News
FEMY
1.270
-4.51%
-0.060
Femasys Releases Updated Investor Presentation Information
TipRanks · 5d ago
Weekly Report: what happened at FEMY last week (0415-0419)?
Weekly Report · 04/22 11:42
Weekly Report: what happened at FEMY last week (0408-0412)?
Weekly Report · 04/15 11:33
Weekly Report: what happened at FEMY last week (0401-0405)?
Weekly Report · 04/08 11:38
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
TipRanks · 04/02 19:45
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Dow Jones · 04/01 12:35
Femasys Is Maintained at Buy by Chardan Capital
Dow Jones · 04/01 12:35
Chardan Capital Maintains Buy on Femasys, Maintains $12 Price Target
Benzinga · 04/01 12:25
Weekly Report: what happened at FEMY last week (0325-0329)?
Weekly Report · 04/01 11:35
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
Femasys just reported results for the fourth quarter of 2023. The company reported earnings per share of -19 cents. Femasys reported revenue of $213,111. This was 11.20% worse than the analyst estimate of $240,000.
Investorplace · 03/29 02:53
Press Release: Femasys Announces Financial -2-
Femasys is a leading biomedical company focused on addressing the unmet needs of women worldwide. The company's lead product candidate is a non-surgical, in-office, permanent birth control method. FemaSeed is an innovative infertility treatment designed to deliver sperm directly where conception occurs. The Company's diagnostic products are FDA-cleared.
Dow Jones · 03/28 20:05
Press Release: Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update. Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations into 2H 2025. Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed for the treatment of infertility.
Dow Jones · 03/28 20:05
Weekly Report: what happened at FEMY last week (0318-0322)?
Weekly Report · 03/25 11:38
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
TipRanks · 03/21 18:30
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Dow Jones · 03/21 17:04
Chardan Capital Reiterates Buy on Femasys, Maintains $12 Price Target
Benzinga · 03/21 16:54
Femasys Is Maintained at Buy by JonesTrading
Dow Jones · 03/21 12:28
Femasys Price Target Raised to $10.00/Share From $7.00 by JonesTrading
Dow Jones · 03/21 12:28
Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)
TipRanks · 03/21 10:31
JAGX and GNPX among Health Care movers
On the Move JAGX and GNPX among Health Care movers. S&P 500 Health Care Sector -0.52% to 1692.4. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is down 0.67%. SCWorx Corp, XTLB, WORX, TFFP, TSHA, FEMY among health care sector gainers.
Seeking Alpha · 03/20 14:13
More
Webull provides a variety of real-time FEMY stock news. You can receive the latest news about FEMASYS INC through multiple platforms. This information may help you make smarter investment decisions.
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.